We are a team of highly renowned experts in the development, production and commercialization of a new drug, which is for the improvement and therapy of different stages of arteriosclerosis.
In 2014 we established our own Clinical Research Laboratory in Mainz. This laboratory was used to work on getting approval for our proprietary drug and where we established the production process. In parallel, we have registered a first clinical study to collect valid data about the BelACT® treatment procedure with the European Clinical Trial Registry. Our innovative therapy for the prevention and treatment of arteriosclerosis and for patients with diagnosed vascular narrowing (stenosis) has been expanded to international country based companies.
PharmACT AG has developed a point-of-care-test (POCT) that one can take, prior to a BelACT therapy. This test, BelDIA PRE®, allows patients to analyze their risk of getting type 2 diabetes and macrovascular diseases. With BelDIA PRE® everyone can easily find out if they are at risk of getting arteriosclerosis or type 2 diabetes.
The POCT is part of our strategy to prevent arteriosclerosis, by diagnosing it at an early stage and starting the treatment.
BelDIA PRE® is a risk screening test where the levels of intact pro-insulin in human capillary blood is measured by means of a lateral-flow based technology. One can rapidly determine if the pancreatic β-cells are failing, which is associated with the development of type 2 diabetes mellitus or other macrovascular complications.
Our risk screening test BelDIA PRE is available in Q1.2017 direct from PharmACT AG and pharmacies.